Clinical Trials & Research Studies in United Kingdom(Updated 8/25)

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06351631

Recruiting

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: * Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; * Essential thrombocythemia (ET) and po... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: University of Michigan ( Site 6000), Ann Arbor, Michigan +20 locations

University of Michigan ( Site 6000), Ann Arbor, Michigan

DUHS Duke Blood Cancer Center ( Site 6005), Durham, North Carolina

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus, Ohio

UPMC Hillman Cancer Center ( Site 6004), Pittsburgh, Pennsylvania

Royal Prince Alfred Hospital ( Site 1003), Camperdown, New South Wales

Royal North Shore Hospital ( Site 1001), St Leonards, New South Wales

Sunshine Coast Hematology and Oncology Clinic ( Site 1006), Buderim, Queensland

Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002), Southport, Queensland

Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000), Adelaide, South Australia

Monash Health ( Site 1004), Clayton, Victoria

Queen Mary Hospital ( Site 1601), Hksar, Not set

Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703), Alessandria, Ancona

Azienda Ospedaliera Universitaria Careggi ( Site 2700), Firenze, Toscana

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702), Bologna, Not set

Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701), Varese, Not set

North Shore Hospital-Department of Haematology ( Site 1401), Auckland, Not set

Aotearoa Clinical Trials ( Site 1400), Auckland, Not set

Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402), London, Hammersmith And Fulham

Boston Pilgrim Hospital ( Site 3403), Boston, Lincolnshire

University College London Hospital ( Site 3400), London, London, City Of

Guy's & St Thomas' NHS Foundation Trust ( Site 3401), London, London, City Of

Conditions: Thrombocythemia, Essential, Primary Myelofibrosis, Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera

Register for Updates

Learn More ›

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318

Recruiting

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/20/2025

Locations: Aalborg Sygehus Syd, Aalborg, Not set +46 locations

Aalborg Sygehus Syd, Aalborg, Not set

Rigshospitalet, Copenhagen, Not set

Odense University Hospital, Odense, Not set

Sygehus Lillebælt, Vejle, Vejle, Not set

Hopital Albert Calmette - CHU Lille, Lille cedex, Not set

Institut Paoli Calmettes, Marseille, Not set

CHU de Nantes hotel Dieu, Nantes, Not set

Hopital Saint Louis, Paris, Not set

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse Cedex 9, Not set

CHRU de Nancy - Hopitaux de Brabois, Vandœuvre-lès-Nancy, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Not set

University Hospital Hamburg Eppendorf, Hamburg, Not set

Uniklinikum Heidelberg, Heidelberg, Not set

Klinikum Nurnberg Nord, Nuernberg, Not set

Universitätsklinikum Würzburg Med. Klinik U. Poliklinik Ii, Wurzburg, Not set

University Hospital of Alexandroupolis, Alexandroupolis, Not set

Cork University Hospital, Cork N/a, Not set

St James Hospital, Dublin, Not set

University Hospital Galway - Ireland, Galway, Not set

Hadassah Medical Center, Jerusalem, Not set

Sheba Medical Center, Ramat Gan, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv Yafo, Not set

Policlinico Sant'Orsola Malpighi, Bologna, Not set

Ospedale A.Perrino di Brindisi, Brindisi, Not set

AOU Careggi, Firenze, Not set

Policlinico di Milano, Milano, Not set

Azienda Ospedaliera Universitaria Federico II, Napoli, Not set

Casa di Cura La Maddalena, Palermo, Not set

Universita Cattolica del Sacro Cuore - Fondazione Policlinico Universitario 'A. Gemelli', Roma, Not set

Presidio Ospedaliero Santo Spirito in Sassia, Roma, Not set

Ospedale Ca' Foncello, Treviso, Not set

Azienda Sanitaria Universitaria Giuliano Isontina Ospedale Maggiore, Trieste, Not set

Hosp. Ntra. Sra. de Sonsoles, Avila, Not set

Hosp. Univ. Virgen de Las Nieves, Granada, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Univ. de La Paz, Madrid, Not set

Hosp. Costa Del Sol, Malaga, Not set

Hosp. Alvaro Cunqueiro, Vigo, Not set

Sahlgrenska University Hospital, Goteborg, Not set

Länssjukhuset Ryhov, Jonkoping, Not set

Karolinska Universitetssjukhuset, Stockholms, Not set

Uddevalla Hospital, Uddevalla, Not set

Queen Elizabeth Hospital, Birmingham, Not set

University College Hospital, London, Not set

Guys and St Thomas NHS Foundation Trust, London, Not set

The Royal Wolverhampton Hospitals NHS Trust - New Cross Hosp, Wolverhampton, Not set

Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Register for Updates

Learn More ›

MEASuRE: Metreleptin Effectiveness And Safety Registry

NCT02325674

Recruiting

The study is a post-authorization, prospective, voluntary registry of patients treated with commercial metreleptin including, but not limited to, patients in the US and EEA.

Gender:

ALL

Ages:

All

Trial Updated:

06/20/2025

Locations: University Alabama at Birmingham, Birmingham, Alabama +27 locations

University Alabama at Birmingham, Birmingham, Alabama

City of Hope, Duarte, California

Atlanta Diabetes Associates, Atlanta, Georgia

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas

Children's Hospital of New Orleans/LSU Health Sciences Center, New Orleans, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Nih/Niddk/Deob, Bethesda, Maryland

University of Michigan, Ann Arbor, Michigan

Childrens Hospital of Michigan, Detroit, Michigan

Richmond University Medical Centre, Staten Island, New York

Endocrinology Research Associates, Columbus, Ohio

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

University of Pennsylvania, Philadelphia, Pennsylvania

UT Southwestern Medical Center, Dallas, Texas

Seattle Children's Hospital, Seattle, Washington

CHRU Hôpital Claude Huriez, Lille, Nord

Hôpital Robert Debré, Paris, Paris, France

Hôpital Saint-Antoine, Paris, Not set

Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg

Kinderkrankenhaus Auf der Bult, Hannover, Niedersachsen

Universitaetsklinikum Muenster, Muenster, Nordrhein Westfalen

Universitaetsklinikum Leipzig AoeR, Leipzig, Sachsen

Universita del Piemonte Orientale "Amedeo Avogadro", Novara, Verceilli

Alma Mater Studiorum - Università di Bologna, Bologna, Not set

Azienda Ospedaliero Universitaria Pisana (Presidio di Cisanello), Pisa, Not set

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Roma, Not set

Addenbrooke's Hospital, Cambridge, Not set

Conditions: Generalised Lipodystrophy, Partial Lipodystrophy

Register for Updates

Learn More ›

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors

NCT06431594

Recruiting

The goal of this study is to assess the safety and tolerability of GSK5733584. The study will also see how the levels of GSK5733584 change over time at different dose amount.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: GSK Investigational Site, Lake Mary, Florida +46 locations

GSK Investigational Site, Lake Mary, Florida

GSK Investigational Site, Fairway, Kansas

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Grand Rapids, Michigan

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, West Valley City, Utah

GSK Investigational Site, Cipoletti Rio Negro, Not set

GSK Investigational Site, Ciudad de Buenos Aires, Not set

GSK Investigational Site, Rosario, Not set

GSK Investigational Site, Blacktown, New South Wales

GSK Investigational Site, Macquarie University, New South Wales

GSK Investigational Site, Leuven, Not set

GSK Investigational Site, Ottawa, Ontario

GSK Investigational Site, Toronto, Ontario

GSK Investigational Site, Montreal, Quebec

GSK Investigational Site, Helsinki, Not set

GSK Investigational Site, Tampere, Not set

GSK Investigational Site, Lyon Cedex 08, Not set

GSK Investigational Site, Saint Herblain, Not set

GSK Investigational Site, Villejuif cedex, Not set

GSK Investigational Site, Roma, Not set

GSK Investigational Site, Rozzano MI, Not set

GSK Investigational Site, Saitama, Not set

GSK Investigational Site, Shizuoka, Not set

GSK Investigational Site, Tokyo, Not set

GSK Investigational Site, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Amsterdam, Not set

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, COrdoba, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Pozuelo De AlarcOn Madr, Not set

GSK Investigational Site, Stockholm, Not set

GSK Investigational Site, Uppsala, Not set

GSK Investigational Site, Cambridge, Not set

GSK Investigational Site, London, Not set

Conditions: Solid Tumors, Neoplasms

Register for Updates

Learn More ›

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

NCT06668181

Recruiting

The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Gender:

ALL

Ages:

Between 2 years and 18 years

Trial Updated:

06/19/2025

Locations: Ja0005 50646, Calgary, Not set +19 locations

Conditions: Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis

Register for Updates

Learn More ›

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

NCT03876054

Recruiting

The REALITY study is a prospective, post-market, non-randomized, multi-center, single-arm, open-label study intended to collect short- and long-term safety and effectiveness data on various populations implanted with Abbott's neurostimulation systems.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: Phoenician Centers for Research & Innovation, Phoenix, Arizona +54 locations

Phoenician Centers for Research & Innovation, Phoenix, Arizona

Pain Institute of Southern Arizona, Tucson, Arizona

California Orthopedics & Spine, Larkspur, California

Restore Orthopedics & Spine Center, Orange, California

Foothills Pain Management Clinic, Pomona, California

Pacific Research Institute, Santa Rosa, California

University of Florida Department of Anesthesia, Gainesville, Florida

Rush University Medical Center, Chicago, Illinois

University of Chicago, Chicago, Illinois

Goodman Campbell Brain and Spine, Indianapolis, Indiana

Nura, Edina, Minnesota

Twin Cities Pain Clinic, Edina, Minnesota

Mayo Clinic, Rochester, Minnesota

Saint Louis Pain Consultants, Chesterfield, Missouri

Advanced Pain Care, Henderson, Nevada

Nevada Advanced Pain Specialists, Reno, Nevada

Ainsworth Institute of Pain Management, New York, New York

Unity Spine Center, Rochester, New York

The Spine & Pain Institute of New York, Staten Island, New York

Premier Pain Solutions, Asheville, North Carolina

Adena Bone and Joint Center, Chillicothe, Ohio

Premier Pain Treatment Institute, Loveland, Ohio

Pacific Sports & Spine, Eugene, Oregon

Spinal Diagnostics, Tualatin, Oregon

Center for Interventional Pain & Spine, Exton, Pennsylvania

Expert Pain, Houston, Texas

Central Texas Pain Institute, Killeen, Texas

Integrated Pain Associates, Killeen, Texas

Advanced Pain Care, Round Rock, Texas

The Spine & Nerve Center of St Francis Hospital, Charleston, West Virginia

Metro Pain Group, Clayton, Victoria

Precision Brain, Spine & Pain Centre, Kew, Victoria

AZ Nikolaas, Sint-Niklaas, Eflndrs

AZ Delta vzw, Roeselare, West Flanders

Universitäts Klinikum Tübingen, Tubingen, Bad-wur

Klinikum Ingolstadt GmbH, Ingolstadt, Bavaria

Klinikum Duisburg GmbH, Duisburg, N. Rhin

Universitaetsklinikum Duesseldorf, Dusseldorf, N. Rhin

Krankenhaus Neuwerk Maria von den Aposteln, Monchengladbach, N. Rhin

Kliniken der Stadt Köln-Merheim, Koln, North Rhine-Westphalia

Universitätsklinikum Schleswig-Holstein, Lübeck, Schleswig-Holstein

Hospital Gera -Zentrum für interdisziplinäre Schmerztherapie, Gera, Thuringia

Krankenhaus Porz am Rhein, Koln, Not set

Azienda Ospedaliera Monaldi, Napoli, Campani

Fondazione Salvatore Maugeri, Pavia, Lombard

Erasmus MC, Rotterdam, S Holln

St. Antonius Ziekenhuis, Nieuwegein, Utrecht

Hospital Universitario de Salamanca, Salamanca, Cstleon

Hospital Universitario Puerta de Hierro, Majadahonda, Madrid

Hospital Universitari i Politècnic La Fe, Valencia, Not set

Hôpital du Valais, Sion, Valais

Norfolk and Norwich Hospital, Norwich, England

The Walton Centre, Liverpool, North West England

Southmead Hospital, Bristol, Sowest

Seacroft Hospital, Leeds, Yorkshire And The Humber

Conditions: Chronic Pain

Register for Updates

Learn More ›

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

NCT06784648

Recruiting

Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically. Melanoma is a type of skin cancer that starts in melanocytes, the cells that make the pigment that gives skin its color. In people with cancer, the body cannot control the growth of cells, which can come together to form tumors. This trial's new treatment is called BI-1607. BI-1607 is designed to work by improving the effectiveness of other targeted therapies al... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: Charité - Universitatsmedizin Berlin, Berlin, Not set +8 locations

Conditions: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent, Melanoma Stage III or IV, Melanoma, Melanoma Negative for BRAF, Melanoma Negative for NRAS, Melanomas, Uveal Melanoma, Metastatic

Register for Updates

Learn More ›

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

NCT05526560

Recruiting

Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: University of Alabama Hospital, Birmingham, Alabama +36 locations

University of Alabama Hospital, Birmingham, Alabama

University of Southern California, Los Angeles, California

Hoag Memorial Hospital Presbyterian, Newport Beach, California

Stanford University, Palo Alto, California

AdventHealth Orlando, Orlando, Florida

Piedmont Heart Institute, Athens, Georgia

Piedmont Heart Institute, Atlanta, Georgia

Ascension St. Vincent Heart Center, Carmel, Indiana

University of Michigan, Ann Arbor, Michigan

Mayo Clinic, Rochester, Rochester, Minnesota

Washington University Barnes-Jewish Hospital, Saint Louis, Missouri

Mount Sinai Hospital, New York, New York

Columbia University Irving Medical Center, New York, New York

Weill Cornell Medicine, New York, New York

Duke University Medical Center, Durham, North Carolina

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

UPMC Presbyterian Shadyside, Pittsburgh, Pennsylvania

Tristar Centennial Medical Center, Nashville, Tennessee

Ascension Saint Thomas, Nashville, Tennessee

University of Utah, Salt Lake City, Utah

Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin

Aurora St. Luke's Medical Center, Milwaukee, Wisconsin

St. Paul's Hospital and Vancouver General Hospital, Vancouver, British Columbia

London Health Sciences Centre, University Hospital (LHSC), London, Ontario

Montreal Heart Institute, Montréal, Quebec

Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Not set

Universitätsklinikum Augsburg, Augsburg, Not set

Rhoen-Klinikum Campus Bad Neustadt, Bad Neustadt, Not set

Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Not set

University Clinic Bonn, Bonn, Not set

Klinikum Links der Weser, Bremen, Not set

Deutsches Herzzentrum München, München, Not set

Royal Papworth Hospital, Cambridge, Not set

St. Thomas Hospital, London, Not set

King's College Hospital, London, Not set

Cleveland Clinic London, London, Not set

Conditions: Mitral Stenosis, Mitral Valve Insufficiency

Register for Updates

Learn More ›

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229

Recruiting

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: Akron Children's Hospital, Akron, Ohio +22 locations

Akron Children's Hospital, Akron, Ohio

The University of Texas Health Science Center at Houston, Houston, Texas

Hopital Universitaire de Bruxelles (H.U.B)/ Academisch Ziekenhuis Brussel, Brussel, Not set

Universitair Ziekenhuis Gent, Gent, Not set

Universitair Ziekenhuis Leuven Gasthuisberg Campus, Leuven, Not set

Copenhagen Neuromuscular Center, Rigshospitalet, Copenhagen, Not set

Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin, Bordeaux, Not set

Hopital Roger Salengro, CHRU de Lille, Lille, Not set

Centre Hospitalier Universitaire de Nice, Hopital Pasteur 2, Nice, Not set

CHU de NICE - Hôpital Archet 2, Nice, Not set

Groupe Hospitalier Pitie-Salpetriere, Paris, Not set

IRCCS Institute of Neurological Sciences of Bologna- Universita di Bologna, Bologna, Not set

Azienda Ospedaliera Universitaria Gaetano Martino Messina, Messina, Not set

Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Not set

Azienda Ospedaliero Universitaria Pisana, Pisa, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Universita Cattolica del Sacro Cuore, Roma, Not set

CIBERER- IDIBAPS, Faculty of Medicine, University of Barcelona, Barcelona, Not set

Hospital de la Santa Creu i Sant Pau, Barcelona, Not set

Hospital General Universitario de Catalunya, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Department of Clinical Neurosciences, Addenbrooke's Hospital, Cambridge, Not set

University College London Hospitals Nhs Foundation Trust, London, Not set

Royal Victoria Infirmary - The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, Not set

Conditions: Primary Mitochondrial Disease

Register for Updates

Learn More ›

STOP Persistent AF PAS

NCT05005949

Recruiting

The STOP Persistent AF Post Approval Study (PAS) is a prospective, global, multicenter, observational trial.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: Hartford Hospital, Hartford, Connecticut +16 locations

Conditions: Persistent Atrial Fibrillation

Register for Updates

Learn More ›

A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

NCT03320304

Recruiting

The primary objective of this study is to assess short, mid and long-term clinical outcomes in patients with difficult to treat depression (such as patients with treatment resistant depression) treated with Vagus Nerve Stimulation (VNS) Therapy as adjunctive therapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: AKH Allgemeines Krankenhaus der Stadt Wien, Vienna, Not set +17 locations

Conditions: Treatment Resistant Depression

Register for Updates

Learn More ›

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT05936359

Recruiting

This study is being conducted to evaluate the safety, tolerability, and dose-limiting toxicity (DLT) and determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of INCA033989 administered as a monotherapy or in combination with ruxolitinib in participants with myeloproliferative neoplasms.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/19/2025

Locations: Royal Brisbane and Women'S Hospital, Herston, Queensland +28 locations

Royal Brisbane and Women'S Hospital, Herston, Queensland

Royal Adelaide Hospital, Adelaide, South Australia

Peter Maccallum Cancer Centre, Melbourne, Victoria

The Alfred Hospital, Melbourne, Victoria

Princess Margaret Cancer Center, Toronto, Ontario

Hopital Maisonneuve-Rosemont, Montreal, Qc, Montreal, Quebec

Odense University Hospital, Odense C, Not set

Sjaellands Universitetshospital, Roskilde, Not set

Vejle Hospital, Vejle, Not set

Institut Bergonie, Bordeaux, Not set

Chu Nimes, Nimes, Not set

Hospital Saint Louis, Paris, Not set

Institut Gustave Roussy, Villejuif Cedex, Not set

University Medical Center Rwth Aachen, Aachen, Not set

Universitatsklinikum Halle (Saale), Halle, Not set

Universitatsklinikum Ulm, ULM, Not set

Aou Policlinico S. Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero-Universitaria Careggi (Aouc), Firenze, Not set

Fondazione Irccs Ca Granda Ospedale Maggiore, Milan, Not set

National Cancer Center Hospital East, Chiba, Not set

Kagoshima University Hospital, Kagoshima, Not set

Osaka Metropolitan University Hospital, Osaka, Not set

Nippon Medical School Hospital, Tokyo, Not set

Mie University Hospital, TSU, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitari I Politecnic La Fe, Valencia, Not set

Guys and St Thomas Nhs Foundation Trust, London, Not set

The Christie Nhs Foundation Trust Uk, Manchester, Not set

University of Oxford, Oxford, Not set

Conditions: Myeloproliferative Neoplasms

Register for Updates

Learn More ›

All Clinical Trials in United Kingdom

Match to Clinical Trials